632 |
ja |
Tremfya; Consentyx; |
A prospective non-interventional study to evaluate Guselkumab real-world effectiveness in different treatment lines in patients with moderate-to severe plaque psoriasis |
acromion GmbH |
Janssen-Cilag GmbH |
12.11.2021 |
752 |
ja |
Enhertu; |
A Prospective non-interventional study (NIS) of trastuzumab deRuxtecan (T-DXd) for adult patients with advanced HER2-pOsitive gaStric or gastroesoPhageal junction (GEJ) adEnocarcinoma who have Received a prIor Trastuzumab-based regimen, accompanied by a disease registrY of patients treated with conventional therapies in a real-world setting in Europe.
Eine prospektive nicht-interventionelle Studie (NIS) zu Trastuzumab-Deruxtecan (T-DXd) bei erwachsenen Patienten mit fortgeschrittenem HER2-positivem Adenokarzinom des Magens oder des gastroösophagealen Übergangs, bei denen zuvor ein Trastuzumab-basiertes Behandlungsschema angewendet wurde, begleitet von einem Krankheitsregister von Patienten, die in der klinischen Routinepraxis in Europa mit konventioneller Therapie behandelt wurden. |
Daiichi Sankyo Europe GmbH |
Diamond (KH) Germany HoldCo GmbH |
15.12.2023 |
576 |
nein |
Trogarzo; |
A Prospective and Retrospective, Observational Multicentre Ibalizumab Study of Efficacy (PROMISE) |
ROKC Research Organisation (KC) Ltd. |
Theratechnologies Europe Limited |
30.04.2021 |
171 |
nein |
HUMIRA |
A Post-Marketing Observational Study (PMOS) to Determine the Effectiveness and Patient Satisfaction with Adalimumab Treatment in Patients with Rheumatoid Arthritis (“PASSION”) |
AbbVie Deutschland GmbH & Co. KG |
|
11.11.2011 |
279 |
ja |
Certolizumab pegol |
A Noninterventional Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Practice |
UCB Biosciences GmbH |
UCB Biopharma SPRL |
11.09.2014 |
773 |
ja |
Fasenra 30 mg Injektionslösung in einer Fertigspritze; Fasenra 30 mg Injektionslösung in einem Fertigpen |
A non-InteRventional, PrOspective study With bEnRalizumab to investigate clinical outcome based on standard of care medication in real-life (AIR POWER) |
AstraZeneca GmbH |
AstraZeneca GmbH |
28.05.2024 |
711 |
ja |
Vabysmo 120 mg/ml Injektionslösung |
A NON-INTERVENTIONAL, MULTICENTER STUDY TO INVESTIGATE EFFECTIVENESS, SAFETY AND QUALITY OF LIFE IN nAMD SWITCH PATIENTS TREATED WITH FARICIMAB UNDER REAL WORLD CONDITIONS IN GERMANY (PASSENGER) |
Roche Pharma AG Grenzach-Wyhlen |
Roche Pharma AG Grenzach-Wyhlen |
27.04.2023 |
381 |
ja |
Vectibix |
A non-interventional study to assess the safety and efficacy of first line therapy with Vectibix® in combination with FOLFIRI or FOLFOX and to validate a prognostic score in adult patients with RAS wild-type metastatic colorectal cancer in a real world setting (VALIDATE) |
iOMEDICO AG Freiburg |
iOMEDICO AG Freiburg |
19.12.2016 |
569 |
ja |
All licensed anti-VEGF injections:; Beovu; Lucentis; Eylea; ; |
A non-interventional study to assess the influence of automated optical coherence tomography (OCT) image enrichment with segmentation information on disease activity assessment in patients treated with licensed anti-VEGF injections (RAZORBILL) |
Novartis Pharma GmbH |
|
16.02.2021 |
568 |
ja |
Kyprolis; Revlimid; Darzalex; |
A non-interventional study of carfilzomib (Kyprolis) in combination with lenalidomide (Revlimid®) and dexamethasone or carfilzomib in combination with dexamethasone alone or carfilzomib in combination with daratumumab (Darzalex) and dexamethasone in patients with multiple myeloma who have received at least one prior therapy |
iOMEDICO AG |
|
16.02.2021 |
690 |
ja |
Kesimpta; |
A non-interventional study evaluating Kesimpta® (ofatumumab) treatment effects in patients with relapsing multiple sclerosis transitioning from other therapies |
Novartis Pharma Vertriebs GmbH |
|
28.10.2022 |
660 |
ja |
Kesimpta; Avonex; Betaferon; Extavia; Copaxone; Clift |
A non-interventional study evaluating injectable treatments (ofatumumab, glatiramer acetate and interferon β1) in patients with relapsing multiple sclerosis |
Novartis Pharma Vertriebs GmbH |
|
25.04.2022 |
385 |
ja |
Nucala |
A Multinational, Single Arm, Observational Study to Evaluate the Real-world Effectiveness and Pattern of Use of Mepolizumab in Patients with Severe Eosinophilic Asthma (204710). |
PPD Germany GmbH & Co KG |
GlaxoSmithKline Research&Development |
26.01.2017 |
517 |
ja |
|
A multinational observational, cross-sectional study to assess disease activity of patients with ankylosing spondylitis treated with Tumour Necrosis Factors Inhibitors (TNFi) and/or Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). INVISIBLE study |
Novartis Pharma GmbH |
|
27.01.2020 |
405 |
ja |
Erelzi 25 mg Injektionslösung in einer Fertigspritze.; Erelzi 50 mg Injektionslösung in einer Fertigspritze; Erelzi 500 mg Injektionslösung in einer Fertigspritze; ; |
A multicenter, prospective, observational cohort study to evaluate the real-world safety and effectiveness of Erelzi™,an etanercept biosimilar (COMPACT) |
Labcorp Clinical Development GmbH |
Hexal AG |
24.08.2017 |
566 |
nein |
|
A Multicenter, Prospective Observational Study to Characterize the Clinical Course of
Pregnant Women and Children at High Risk for Early Onset Severe Hemolytic Disease of
the Fetus and Newborn
/ Eine multizentrische, prospektive Beobachtungsstudie zur Charakterisierung des klinischen Verlaufs bei schwangeren Frauen und Kindern mit einem hohem Risiko für eine Frühform der schweren hämolytischen Erkrankung des Fötus und Neugeborenen |
|
Janssen (former Momenta Pharmaceuticals, Inc) |
10.02.2021 |
621 |
ja |
Ilumetri 100 mg Injektionslösung in einer Fertigspritze; |
A multicenter, prospective observational RWE study to assess Patient-reported wellbeing using tildrakizumab in a live setting - POSITIVE study |
IQVIA RDS GmbH |
Almirall |
29.09.2021 |
605 |
ja |
MS dose modifying therapies; SARS-Cov-2-vaccines |
A multicenter, prospective cohort study to document the immunization status of MS patients in Germany with focus on anti-SARS-CoV-2 vaccination response |
CLINVICES GmbH |
BIOGEN GmbH |
15.07.2021 |
72 |
nein |
Cimzia |
A MULTICENTER, OBSERVATIONAL, NONINTERVENTIONAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ANTI TNF ALPHA THERAPY WITH CERTOLIZUMAB PEGOL OBSERVED IN DAILY PRACTICE IN ADULT RHEUMATOID ARTHRITIS (RA) PATIENTS |
UCB Biopharma SPRL |
UCB Pharma GmbH |
06.10.2009 |
479 |
ja |
Cimzia; |
A MULTICENTER, NONINTERVENTIONAL, PROSPECTIVE STUDY TO ASSESS THE EFFECTIVENESS OF CERTOLIZUMAB PEGOL IN PATIENTS WITH MODERATE TO
SEVERE PLAQUE PSORIASIS IN DAILY PRACTICE (CIMREAL) |
Parexel Int GmbH |
UCB Biopharma SPRL |
07.05.2019 |
308 |
nein |
Unspezifische Erfassung aller verordneten Medikamente der beobachteten Hämophilie-Patienten |
A MULTICENTER, NON-INTERVENTIONAL STUDY EVALUATING BLEEDING INCIDENCE,
HEALTH-RELATED QUALITY OF LIFE, AND SAFETY IN PATIENTS WITH HEMOPHILIA A
UNDER STANDARD-OF-CARE TREATMENT |
Roche Pharma AG |
Hoffmann la Roche, Basel, Schweiz |
09.07.2015 |
220 |
nein |
Certolizumab Pegol; Adalimumab ; Etanercept; Golimumab ; |
A MULTICENTER NONINTERVENTIONAL STUDY WITH CERTOLIZUMAB PEGOL IN COMPARISON WITH ANY OTHER SUBCUTANEOUS TNF INHIBITOR IN TWO PARALLEL GROUPS IN BIOLOGIC NAIVE PATIENTS WITH RHEUMATOID ARTHRITIS |
Parexel International GmbH |
UCB Pharma SA |
05.12.2012 |
191 |
nein |
Yervoy |
A Multi-National, Prospective, Observational Study in Patients with Advanced Unresectable or Metastatic Melanoma |
Bristol-Myers-Squibb GmbH & Co. KG aA |
Bristol-Myers-Squibb Belgien |
17.04.2012 |
363 |
nein |
|
A Multi-Center Retrospective Observational Study to Evaluate PD-L1 Protein Expression in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
PAREXEL International GmbH |
Merck Sharp & Dohme Corp. |
30.06.2016 |
160 |
ja |
HUMIRA |
A Long-term, Multi-center, Longitudinal Post-marketing, Observational Registry to Assess Long Term Safety and Effectiveness of HUMIRA (Adalimumab) in Children with Moderate to Severe Active Polyarticular or Polyarticular Course Juvenile Idiopathic Arthritis (JIA) - "STRIVE" |
AbbVie Deutschland GmbH & Co. KG |
|
04.12.2009 |